Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. 

Pharmaceutical

Paradigm Biopharma

Paul Rennie

Jill Forrest

Catherine Stapledon

Donna Skerrett M.D. Msc

Simon White

Justin Cahill

Donna Skerrett

Michelle Coffey

Leadership Team

Clinical Operations Team

Regulatory and Scientific Affairs Team

Finance and Investor Relations Team

Teams at Paradigm Biopharma

Leadership Team

Clinical Operations Team

Regulatory and Scientific Affairs Team

Finance and Investor Relations Team